Success in Response to COVID-19 Pandemic Has Gained Recognition

23 April 2020

We are honored to share that Vivantis Technologies Sdn Bhd (Vivantis) as a BioNexus status company in Malaysia has gained recognition by several media and press for playing an essential role in assisting the medical and health authorities with the immediate supply of RNA extraction kits for use in COVID-19 tests and helping fight the COVID-19 pandemic.

With the emergence of the Coronavirus Disease 2019 (COVID-19) which previously identified as 2019 novel coronavirus (2019-nCoV) infection in China, the company has donated and supplied GF-1 Nucleic Acid Extraction Kits to several COVID-19 authorized testing laboratories in Malaysia.

GF-1 Viral Nucleic Acid Extraction Kit can be used to extract RNA strands from samples such as virus-infected biological samples and purify them so they can be used for downstream applications, such as RT-qPCR and library prep for next generation sequencing and matched for signs of the novel coronavirus SARS-CoV-2, which lead to the pandemic disease COVID-19.

“We at Vivantis understand that the need for supplies and support for scientists working to restrain spread of the coronavirus is crucial and immediate. As such, we wish to work with our customers around the world to assess their resource needs to address COVID-19 crisis in this critical time,” said Law Eng Lim, CEO of Vivantis.

“Vivantis’s products are intended for research purposes only. However, we are already supplying and supporting customers who are working relentlessly to develop better diagnostics tools for the COVID-19 virus and are prepared to supply additional customers with the reagents they need to validate and develop them as diagnostic tools for lab-based or point-of-care settings,” he said.

With comprehensive portfolio of research reagents, Vivantis is prepared to supports researchers around the globe in their work towards understanding this emerging virus by providing collaborative technical support, nucleic acid purification tools and expertise, amplification products and RT-qPCR technologies that streamline research workflow.

Please browse through the list of media and press coverage below to learn more about the story behind GF-1 Viral Nucleic Acid Extraction Kit and how the company evolves from its humble inception and currently playing a part in national security to capitalize on biotechnology to address COVID-19 crisis with the supply of GF-1 Viral Nucleic Acid Extraction for the country and also to assist other nations especially the developing countries in combating the invasive disease amid the current disruption in global supply chain.

Vivantis CEO on Astro Awani: Effort of Technology Sector in Addressing COVID-19
Agenda Awani: Usaha sector teknologi tangani COVID-19,
12 April 2020